id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0513-0017,FDA,FDA-2011-N-0513,"FDA/OC/CDER to G. Matthew Warren, Senior Regulatory Counsel, March 30, 2012- Letter",Other,Letter(s),2012-04-02T04:00:00Z,2012,4,2012-04-02T04:00:00Z,,2012-04-02T13:55:23Z,,0,0,0900006480fe5c91
FDA-2011-N-0513-0016,FDA,FDA-2011-N-0513,"FDA/OC/CDER to G. Matthew Warren, Senior Regulatory Counsel, February 17, 2012- Letter",Other,Letter(s),2012-02-21T05:00:00Z,2012,2,2012-02-21T05:00:00Z,,2012-02-21T16:57:50Z,,0,0,0900006480fbaca1
FDA-2011-N-0513-0015,FDA,FDA-2011-N-0513,"ISTA Pharmaceuticals, Inc. (Covington & Burling, LLP) February 2, 2012 - Letter",Other,Letter(s),2012-02-16T05:00:00Z,2012,2,2012-02-16T05:00:00Z,,2012-02-21T16:40:27Z,,0,0,0900006480fb87df
FDA-2011-N-0513-0012,FDA,FDA-2011-N-0513,Covington & Burling - Letter,Other,Letter(s),2012-01-24T05:00:00Z,2012,1,2012-01-24T05:00:00Z,,2012-01-24T16:22:50Z,,0,0,0900006480f89793
FDA-2011-N-0513-0014,FDA,FDA-2011-N-0513,"FDA/OC/CDER to G. Matthew Warren, Senior Regulatory Counsel - Letter",Other,Letter(s),2012-01-24T05:00:00Z,2012,1,2012-01-24T05:00:00Z,,2012-01-24T16:51:20Z,,0,0,0900006480fa2836
FDA-2011-N-0513-0013,FDA,FDA-2011-N-0513,"FDA/OC Letter to Parties from the Office of the Commissioner, dated December 30, 2011 - Letter",Other,Letter(s),2012-01-24T05:00:00Z,2012,1,2012-01-24T05:00:00Z,,2012-01-24T16:27:54Z,,0,0,0900006480fa27a9
FDA-2011-N-0513-0011,FDA,FDA-2011-N-0513,"ISTA Pharmaceuticals, Inc. (Covington & Burling, LLP) - Letter",Other,Letter(s),2012-01-24T05:00:00Z,2012,1,2012-01-24T05:00:00Z,,2012-01-24T16:20:10Z,,0,0,0900006480f8a7cf